CASES AND TRACES

An Irregular Wide Complex Tachycardia

ECG CHALLENGE

A 66-year-old woman with a history of hypertension and persistent atrial fibrilla-
tion was referred to the Arrhythmia Clinic. Before her visit, a routine 12-lead ECG
was ordered (Figure 1). The patient was asymptomatic except for minor palpita-
tions. Her medicine regimen included apixaban, flecainide 150 mg twice daily,
lisinopril, loratadine, metoprolol, and simvastatin.
What is the cardiac rhythm and what should be the initial treatment?
Please turn the page to read the diagnosis.

Figure 1. Routine 12-lead ECG recorded before a clinic visit to the electrophysiolo-

Correspondence to: G. Neal Kay, MD, Division of Cardiovascular Disease, Department of Medicine, 921 Faculty Office Tower, University of Alabama at Birmingham, Birmingham, AL 35294. E-mail nealkay@hotmail.com

Key Words: drug toxicity • flecainide • ventricular tachycardia

© 2017 American Heart Association, Inc.
RESPONSE TO ECG CHALLENGE

The ECG shows a very wide QRS complex tachycardia (QRS duration 280 ms) with variation in morphology. Following a pause of 700 ms, there are repeating sequences of 6 to 7 beats with cycle lengths of 400 to 415 ms. A second ECG demonstrated that the QRS morphology changed from a right bundle-branch block type pattern to a left bundle-branch block type pattern in lead V1 (Figure 2). On interruption of the tachycardia, atrial fibrillation with an atypical left bundle-branch block was observed followed by resumption of the wide complex tachycardia. These features are consistent with flecainide-induced, pleomorphic ventricular tachycardia.

An intravenous bolus of sodium bicarbonate was given in the clinic with return to atrial fibrillation (Figure 3). Prior medical records showed QRS duration of 84 ms before initiating flecainide with a normal echocardiogram and nuclear stress test. On admission to the hospital, the serum flecainide level measured 1.8 μg/mL.

Figure 2. A 12-lead ECG recorded within minutes after the ECG in Figure 1, demonstrating ventricular tachycardia with an upright QRS in lead V1, with variable morphology in lead III for 6 beats (*). The ventricular tachycardia morphology spontaneously changes to an inverted QRS in lead V1, for 7 beats (**). Following spontaneous termination of the ventricular tachycardia, the underlying rhythm is atrial fibrillation with an atypical left bundle-branch block conduction. This is followed by the occurrence of 3 beats of an upright QRS ventricular tachycardia in lead V1, for 3 beats (*) that changes to an inverted QRS in lead V1. The patient had only minor palpitations during this period. This ECG is consistent with a pleomorphic ventricular tachycardia that is a proarrhythmic complication of flecainide therapy.

Figure 3. The 12-lead ECG recorded immediately following an intravenous bolus of sodium bicarbonate. The underlying rhythm is atrial fibrillation conducted with left bundle-branch block. The QRS complex remains prolonged with a duration of 180 ms, probably because of the effect of flecainide on conduction in the left bundle branch because the QRS had been normal (84 ms in duration) before initiation of flecainide.
Flecainide has a high affinity for open-state Na+ channels with slow unbinding kinetics. Flecainide also blocks the rapid component of the delayed rectifier current (I_{Kr}) and reduces spontaneous sarcoplasmic reticulum Ca^{2+} release by inhibiting ryanodine receptors. The mechanism of flecainide-induced ventricular tachycardia is uncertain. In canine studies, ventricular tachycardia (VT) was inducible with programmed stimulation after flecainide loading in 4 of 13 healthy dogs (31%) in comparison with 15 of 19 dogs after myocardial infarction. Spontaneous VT occurred in 8 of 19 dogs with prior myocardial infarction but in no healthy dogs. Rate-dependent conduction block transverse to fiber orientation was observed. In the present patient, the first and subsequent beats of each sequence of VT were similar in morphology, suggesting a focal mechanism, consistent with ECG and action potential recordings from isolated perfused guinea pig hearts treated with flecainide. Flecainide prolongs action potential duration significantly more in the left than in the right ventricle, thereby increasing action potential duration dispersion. In animal models, the ECG morphology of the first and subsequent beats of spontaneous VT had a consistent morphology suggesting a focal mechanism. In the present case, the spontaneous change from a right bundle-branch block to a left bundle-branch block QRS pattern during longer episodes of VT is consistent with either reentry or induction of a second focal mechanism.

VT induced by class 1C agents may be resistant to direct current cardioversion. Sodium bicarbonate is effective by increasing serum sodium concentration, thereby competing with the drug for negatively charged sodium channels. In addition, alkalinization shifts more of the drug to the negatively charged state, thereby reducing its entry into sodium channels.

Our patient was treated by discontinuation of flecainide and catheter ablation of atrial fibrillation.

DISCLOSURES
None.

AFFILIATION
From Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham.

FOOTNOTES
Circulation is available at http://circ.ahajournals.org.

REFERENCES
An Irregular Wide Complex Tachycardia
Thomas E. Watts, H. Thomas McElderry and G. Neal Kay

*Circulation*. 2017;136:773-775
doi: 10.1161/CIRCULATIONAHA.117.029974

*Circulation* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2017 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/136/8/773

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Circulation* is online at:
http://circ.ahajournals.org/subscriptions/